BioXcel Therapeutics is a clinical stage biopharmaceutical company utilizing artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology. Co.'s two key clinical development programs are BXCL501, an investigational, proprietary, orally dissolving, sublingual thin film formulation of the adrenergic receptor agonist dexmedetomidine for the treatment of agitation resulting from neuropsychiatric disorders, and BXCL701, an investigational orally administered systemic innate immune activator for the treatment of a rare form of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors. We show 23 historical shares outstanding datapoints in our BTAI shares outstanding history coverage, used to compute BTAI market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing BTAI market cap history over the course of time is important for investors
interested in comparing BTAI's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of BTAI versus a peer is one thing; comparing
BTAI market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like BTAI can fluctuate over the course of history.
With this page we aim to empower investors researching BTAI by allowing them to research the BTAI market cap history. |
Free BTAI Email Alerts:
Video: The Importance of Market Cap
